June payrolls added just 57,000 jobs, well below the 110,000 forecast, leaving the Fed with mixed signals on when to cut rates. D.A. Davidson upgraded PLTR to buy with a $175 target, arguing ...

Stock Market News, July 2, 2026: Dow climbs almost 600 points to a record finish, S&P 500 ends flat and Nasdaq lower as the rotation trade grips markets after June jobs data The Dow cements its 20th ...

Hyperscale Data is transitioning from Bitcoin mining to AI data centers as it remains unprofitable and faces significant maturing debt in 2026. The company is set to dilute shareholders at a material ...

A gunman who allegedly obsessed over the Columbine school massacre before shooting two people dead in a Northern California library has been identified. Cops released a mug shot for Bradley Scott ...

VRT's $15 billion backlog, up 109% year-over-year, supports a bull-case price target of $410, despite shares pulling back 18% last month. Reaching $400 demands EMEA recovery, continued AI order ...

While Excel is ubiquitous, I prefer Python for my data analysis. Spreadsheets are great for formatting data, but it's Python that's allowed me to build my own super calculator out of regular Python ...

Nathan Round, part of GameRant's talented Game Guides Team, is the leading voice for Call of Duty guides. From meta loadouts to the best weapons for each season, he takes pride in crafting top-notch ...

Shares in Dell opened nearly 34% higher Friday, after soaring about 40% in after-hours trading Thursday, when the computer hardware maker reported red-hot growth in artificial-intelligence servers for ...

Shares in the AI data cloud provider Snowflake Inc (NYSE: SNOW) are surging this morning in premarket trading after the company reported better-than-expected results for its Q1 2027. Here’s what you ...

Entrada Therapeutics’ Duchenne muscular dystrophy (DMD) data have fallen well short of expectations, crashing the biotech’s stock as investors evaluated the fallout from a key readout expected to ...

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...